Kyverna’s CAR T Therapy Sets ’New Efficacy Standard’ in Myasthenia Gravis, De-Risking Phase III Trials

With a 100% response rate in a Phase II study, KYV-101 sets a new efficacy bar in generalized myasthenia gravis, according to analysts at William Blair.